PMC:7696151 / 68102-68493
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1970 | 49-57 | Species | denotes | patients | Tax:9606 |
| 1981 | 129-132 | Chemical | denotes | MXT | MESH:D008727 |
| 1982 | 145-159 | Chemical | denotes | sulphasalazine | MESH:D012460 |
| 1983 | 176-179 | Chemical | denotes | HCQ | MESH:D006886 |
| 1984 | 240-258 | Chemical | denotes | methylprednisolone | MESH:D008775 |
| 1985 | 271-284 | Chemical | denotes | triamcinolone | MESH:D014221 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T437 | 0-391 | Sentence | denotes | Likewise, a single-blinded clinical trial on 281 patients confirmed the better therapeutic efficiency of cotreatment (25 mg/week MXT, 2 g/day of sulphasalazine, and 400 mg/day HCQ p.o. plus intramuscular injection (i.m.) doses of 120 mg of methylprednisolone or 80 mg of triamcinolone) with respect to single therapy after three months, without significant differences in side effects [125]. |